Dipòsit Digital de Documents de la UAB
Publication
Artículo científico (JournalArticle)
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. SMARCA4-mutant cells also show an impaired transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX and KDM6B/JMJD3, and a strong dependency on these histone demethylases, so that its inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT), had strong anti-tumour effects. In this work we highlight the vulnerability of KDM6 inhibitors as a characteristic that could be exploited for treating SMARCA4-mutant cancer patients.
Project:
European Commission 799850
,
Ministerio de Economía y Competitividad BES-2015-072204
,
Ministerio de Economía y Competitividad FPU17/00067
,
Ministerio de Economía y Competitividad IJCI-2016-28201
,
Ministerio de Economía y Competitividad PRE2018-084624
,
Agencia Estatal de Investigación SAF-2017-82186R
,
Instituto de Salud Carlos III CM17/00180
,
Instituto de Salud Carlos III PI19/01320
,
Agència de Gestió d'Ajuts Universitaris i de Recerca 2014/SGR-364